Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GlaxoSmithKline ( (GB:GSK) ) has provided an announcement.
GSK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended expanding the approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of adult patients with advanced or recurrent endometrial cancer. If approved, this expansion would include the majority of endometrial cancer cases, potentially transforming treatment options and improving patient outcomes. The decision is expected in the first quarter of 2025, and is based on promising data from the phase III RUBY trial, showcasing significant benefits in progression-free and overall survival.
More about GlaxoSmithKline
GSK is a global biopharma company focused on uniting science, technology, and talent to advance disease treatment. The company is committed to breakthroughs in immuno-oncology and tumour-cell targeting therapies, with a focus on haematologic malignancies, gynaecologic cancers, and other solid tumours.
YTD Price Performance: -4.72%
Average Trading Volume: 8,861,590
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £54.25B
See more data about GSK stock on TipRanks’ Stock Analysis page.
